Patents Assigned to Bayer Pharma Aktiengesellschaft
  • Patent number: 10442772
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: October 15, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Rehwinkel, Olaf Panknin, Sven Ring, Sonja Anlauf, Holger Siebeneicher, Duy Nguyen, Wolfgang Schwede, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus, Paul Matthew Blaney
  • Patent number: 10435403
    Abstract: The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: October 8, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Henrik Teller, Alexander Straub, Markus Brechmann, Thomas Müller, Mark Meininghaus, Katrin Nowak-Reppel, Hanna Tinel, Klaus Münter, Daniela Fliegner, Thomas Mondritzki, Melissa Boultadakis Arapinis, Tobias Marquardt, Alexandros Vakalopoulos, Anne-Sophie Rebstock, Matthias Beat Wittwer
  • Publication number: 20190298865
    Abstract: The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting prolyl endopeptidase FAP; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising administration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided.
    Type: Application
    Filed: June 6, 2017
    Publication date: October 3, 2019
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AS
    Inventors: Alan CUTHBERTSON, Mark TRAUTWEIN, Ernst WEBER, Jenny KARLSSON, Stefanie HAMMER
  • Patent number: 10428044
    Abstract: Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: October 1, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Keith Graham, Ulrich Klar, Hans Briem, Marion Hitchcock, Lars Bärfacker, Knut Eis, Volker Schulze, Gerhard Siemeister, Wilhelm Bone, Jens Schröder, Simon Holton, Philip Lienau, René Tempel, Helmut Sonnenschein, Jozsef Bálint, Heinz Graubaum
  • Patent number: 10428063
    Abstract: Compound of formula (I), processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: October 1, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Keith Graham, Ulrich Klar, Hans Briem, Volker Schulze, Gerhard Siemeister, Philip Lienau, René Tempel, Jozsef Bálint
  • Patent number: 10428083
    Abstract: The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: October 1, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Michael Härter, Dirk Kosemund, Martina Delbeck, Bernd Kalthof, Pierre Wasnaire, Frank Süβmeier, Klemens Lustig
  • Patent number: 10421742
    Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: September 24, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Eloisa Jimenez Nunez, Jens Ackerstaff, Susanne Röhrig, Alexander Hillisch, Katharina Meier, Stefan Heitmeier, Adrian Tersteegen, Jan Stampfuß, Pascal Ellerbrock, Daniel Meibom, Dieter Lang
  • Publication number: 20190284300
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 19, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
  • Publication number: 20190284206
    Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: March 21, 2019
    Publication date: September 19, 2019
    Applicants: Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesellschaft
    Inventors: Marion HITCHCOCK, Anne MENGEL, Vera PÜTTER, Gerhard SIEMEISTER, Antje Margret WENGNER, Hans BRIEM, Knut EIS, Volker SCHULZE, Amaury Ernesto FERNANDEZ-MONTALVAN, Stefan PRECHTL, Simon HOLTON, Jörg FANGHÄNEL, Philip LIENAU, Cornelia PREUSSE, Mark Jean GNOTH
  • Patent number: 10414731
    Abstract: The invention relates to substituted oxopyridine derivatives of formula (I) and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: September 17, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Susanne Röhrig, Alexander Hillisch, Stefan Heitmeier, Martina Victoria Schmidt, Karl-Heinz Schlemmer, Adrian Tersteegen, Henrik Teller
  • Patent number: 10414734
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6 and R7 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: September 17, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf Panknin, Sven Ring, Katja Zimmermann, Roland Neuhaus
  • Patent number: 10414765
    Abstract: The present application relates to novel (2-phenylimidazo[1,2-a]pyridin-3-yl)methyl-substituted perhydropyrrolo[3,4-c]pyrrole derivatives, to methods for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apneas and central sleep apneas and snoring.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: September 17, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Martina Delbeck, Michael Hahn, Thomas Müller, Heinrich Meier, Klemens Lustig, Johanna Mosig, Luisella Toschi, Udo Albus, Doris Gehring, Björn Rosenstein
  • Patent number: 10406162
    Abstract: The present invention relates to * combinations of: ? component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2), or a physiologically acceptable salt, solvate, hydrate or ? stereoisomer thereof; ? component B: one or more substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]-triazin-4-amine compounds of general formula (B), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; ? in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially, ? dependently of one another by the oral, intravenous, topical, local installations, ? intraperitoneal or nasal route; * use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer; * a kit comprising such a combination; * use of biomarkers which is the loss of tumor suppressor PTEN or FBXW7, for predicting the sensitivi
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: September 10, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ningshu Liu, Carol Pena, Michael Jeffers, Isabelle Genvresse
  • Patent number: 10407489
    Abstract: A method for the production of freeze-dried pellets comprising factor VIII comprises the steps of: a) freezing droplets of a solution comprising factor VIII to form pellets; b) freeze-drying the pellets; wherein in step a) the droplets are formed by means of droplet formation of the solution comprising factor VIII into a cooling tower which has a temperature-controllable inner wall surface and an interior temperature below the freezing temperature of the solution and wherein in step b) the pellets are freeze-dried in a rotating receptacle which is housed inside a vacuum chamber.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: September 10, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Carsten Olbrich, Matthias Plitzko, Bernhard Luy, Stefan Christian Schneid
  • Patent number: 10399977
    Abstract: The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and also the preparation and use of the crystalline polymorph I of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I).
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: September 3, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Johannes Platzek, Gunnar Garke, Alfons Grunenberg
  • Publication number: 20190262463
    Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: August 29, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg LERCHEN, Yolanda CANCHO GRANDE, Beatrix STELTE-LUDWIG, Anette SOMMER, Christoph MAHLERT, Anne-Sophie REBSTOCK, Simone GREVEN, Nils GRIEBENOW, Jan TEBBE, Oliver KENSCH
  • Patent number: 10392384
    Abstract: The present invention relates to a novel process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and recovering (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) proceeding from (4R)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula ent-(I)
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: August 27, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Johannes Platzek, Kathrin Gottfried, Jens Assmann, Giulio Lolli
  • Publication number: 20190255063
    Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being venetoclax or palbociclib.
    Type: Application
    Filed: September 15, 2017
    Publication date: August 22, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventor: Martin LANGE
  • Publication number: 20190248783
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: July 2, 2018
    Publication date: August 15, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros VAKALOPOULOS, Markus FOLLMAN, Ingo HARTUNG, Philipp BUCHGRABER, Rolf JAUTELAT, Jorma HAßFELD, Niels LINDNER, Alexey GROMOV, Frank WUNDER, Johannes-Peter STASCH, Gorden REDLICH, Volkhart Min-Jian LI, Eva Maria BECKER-PELSTER, Andreas KNORR
  • Publication number: 20190240231
    Abstract: Combination therapy with rivaroxaban and aspirin successfully reduces the risk of cardiovascular events in patients who have coronary artery disease and/or peripheral artery disease.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 8, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Nancy Cook Bruns, Frank Misselwitz, John William Andrew Eikelboom, Stuart J. Connolly, Salim Yusuf